High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass

Blood

Volumn 121, Issue 15, 2013, Pages 2828-2835

  Lee, Grace M ^a   Welsby, Ian J ^a   Phillips Bute, Barbara ^a   Ortel, Thomas L ^a   Arepally, Gowthami M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEPARIN; INSULIN; PROTAMINE; PROTAMINE HEPARIN ANTIBODY; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; HEPARIN ANTAGONIST; ISOPHANE INSULIN; THROMBOCYTE FACTOR 4;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSS REACTION; FEMALE; HEART SURGERY; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEIN BINDING; STATISTICAL MODEL; THROMBOCYTOPENIA; TIME;

AGED; ANTIBODIES; ANTICOAGULANTS; CARDIOPULMONARY BYPASS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; INCIDENCE; INSULIN, ISOPHANE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET FACTOR 4; PROTAMINES; PROTEIN BINDING; THROMBOCYTOPENIA; TIME FACTORS;

MLCS; MLOWN;

EID: 84878649344     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-469130     Document Type: Article

References (42)

1. Weiss ME, Nyhan D, Peng ZK, Horrow JC, Lowenstein E, Hirshman C, Adkinson NF Jr. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med. 1989;320(14):886-892. (Pubitemid 19101592)
2. Weiler JM, Gellhaus MA, Carter JG, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol. 1990;85(4):713-719. (Pubitemid 20141135)
3. Kimmel SE, Sekeres MA, Berlin JA, Goldberg LR, Strom BL. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J Clin Epidemiol. 1998;51(1):1-10. (Pubitemid 28026509)
4. Kimmel SE, Sekeres M, Berlin JA, Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg. 2002;94(6):1402-1408. [table of contents.] (Pubitemid 34556613)
5. Kimmel SE, Sekeres MA, Berlin JA, Ellison N, DiSesa VJ, Strom BL. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. J Am Coll Cardiol. 1998;32(7):1916-1922. (Pubitemid 29010455)
6. Welsby IJ, Newman MF, Phillips-Bute B, Messier RH, Kakkis ED, Stafford-Smith M. Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery. Anesthesiology. 2005;102(2):308-314. (Pubitemid 40189077)
7. Chudasama SL, Espinasse B, Hwang F, et al. Heparin modifies the immunogenicity of positively charged proteins. Blood. 2010;116(26):6046-6053.
8. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Thrombocytopenia H-I, ed. Warkentin TEG, Andreas, 4th ed. New York: Informa Healthcare USA, Inc; 2007:227-260
9. Hannan EL, Wu C, Bennett EV, et al. Risk stratification of in-hospital mortality for coronary artery bypass graft surgery. J Am Coll Cardiol. 2006;47(3):661-668. (Pubitemid 43170860)
10. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95(5):1242-1246. (Pubitemid 27097836)
11. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99(19):2530-2536. (Pubitemid 29228283)
12. Trossaërt M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol. 1998;101(4):653-655.
13. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703-1708. (Pubitemid 30661052)
14. Chargaff E, Olson KB. Studies on the Chemistry of Blood Coagulation. J Biol Chem. 1937;122:177-180.
15. Hagedorn HCJB, Krarup NB, Wodstrup I. Protamine Insulinate. JAMA. 1936;106(3):177-180.
16. Schnitzler S, Renner H, Pfüller U. Histamine release from rat mast cells induced by protamine sulfate and polyethylene imine. Agents Actions. 1981;11(1-2):73-74. (Pubitemid 11068383)
17. Frater RW, Oka Y, Hong Y, Tsubo T, Loubser PG, Masone R. Protamine-induced circulatory changes. J Thorac Cardiovasc Surg. 1984;87(5):687-692. (Pubitemid 14101249)
18. Takada A, Takada Y. Interaction of C1s and C1 inactivator in the presence of heparin, dextran sulfate and protamine sulfate. Thromb Res. 1980;18(6):847-859. (Pubitemid 10036561)
19. Shastri KA, Logue GL, Stern MP, Rehman S, Raza S. Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4A null allele. J Thorac Cardiovasc Surg. 1997;114(3):482-488. (Pubitemid 27400884)
20. Al-Mondhiry H, Pierce WS, Basarab RM. Protamine-induced thrombocytopenia and leukopenia. Thromb Haemost. 1985;53(1):60-64. (Pubitemid 15135236)
21. Ellerhorst JA, Comstock JP, Nell LJ. Protamine antibody production in diabetic subjects treated with NPH insulin. Am J Med Sci. 1990;299(5):298-301. (Pubitemid 20166482)
22. Nell LJ, Thomas JW. Frequency and specificity of protamine antibodies in diabetic and control subjects. Diabetes. 1988;37(2):172-176. (Pubitemid 18066600)
23. Gottschlich GM, Gravlee GP, Georgitis JW. Adverse reactions to protamine sulfate during cardiac surgery in diabetic and non-diabetic patients. Ann Allergy. 1988;61(4):277-281.
24. Stewart WJ, McSweeney SM, Kellett MA, Faxon DP, Ryan TJ. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. Circulation. 1984;70(5):788-792. (Pubitemid 15205442)
25. Weiss ME, Adkinson NF Jr. Allergy to protamine. Clin Rev Allergy. 1991;9(3-4):339-355.
26. Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart Lung. 1999;28(6):418-428.
27. Weiler JM, Freiman P, Sharath MD, et al. Serious adverse reactions to protamine sulfate: are alternatives needed? J Allergy Clin Immunol. 1985;75(2):297-303. (Pubitemid 15239085)
28. Adourian U, Shampaine EL, Hirshman CA, Fuchs E, Adkinson NF Jr. High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized men. Anesthesiology. 1993;78(2):368-372. (Pubitemid 23069561)
29. Horrow JC. Protamine: a review of its toxicity. Anesth Analg. 1985;64(3):348-361. (Pubitemid 15130775)
30. Hellema HW, Samuel T, Rumke P. Sperm autoantibodies as a consequence of vasectomy. II. Long-term follow-up studies. Clin Exp Immunol. 1979;38(1):31-36. (Pubitemid 9242142)
31. Bakchoul T, Zöllner H, Amiral J, et al. Antiprotamine-heparin antibodies: incidence, clinical relevance and pathogenesis. Blood. 2013. January [Epub ahead of pring]
32. Pouplard C, Leroux D, et al. Incidence of antibodies to protamine sulfate/heparin complexes in cardiac surgery patients and impact on platelet activation and clinical outcome. J Thromb Haemost. 2012. (in press)
33. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72(3):925-930.
34. Pouplard C. Leroux D, Rollin J, et al. Incidene of antibodies to protamine/heparin complexes in cardiac surgery patients and impact on platelet activation in vitro and clinical outcome. In: 53rd American Society of Hematology Annual Meeting and Exposition; December 10-13, 2011; San Diego, CA. Abstract 2217.
35. Gluckman TJ, Segal JB, Schulman SP, et al. Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. J Thromb Haemost. 2009;7(9):1457-1464.
36. Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol. 1997;99(2):273-280. (Pubitemid 27497551)
37. Schwab C, Bosshard HR. Caveats for the use of surface-adsorbed protein antigen to test the specificity of antibodies. J Immunol Methods. 1992;147(1):125-134.
38. Alberio L, Kimmerle S, Baumann A, Taleghani BM, Biasiutti FD, Lämmle B. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med. 2003;114(7):528-536. (Pubitemid 36577255)
39. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2(12):2133-2137. (Pubitemid 40185772)
40. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med. 2005;146(6):341-346. (Pubitemid 41712020)
41. Keeler JF, Hansbro SD, Shah MV. Protamine - What dose? J Cardiothorac Anesth. 1990;4:41.
42. Singla A, Sullivan M, Lee GM, et al. Protamine-induced immune thrombocytopenia. Transfusion. 2013. February 4 [Epub ahead of print]